Vejle

• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination … Recruiting
  2023-503442-30-00 5 2022-10-14 Multiple Myeloma
• Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Dia … Recruiting
  2023-510384-36-00 5 2022-09-13 Newly Diagnosed Multiple Myeloma
• OPTIMISE Recruiting
  2023-509814-12-00 4 2021-09-22 Colorectal cancer with metastasis
• ProTarget - A Danish Nationwide Clinical Trial on Targeted Anti‐Cancer Treatment based on Genomic Profiling Recruiting
  2023-510527-29-00 4 2020-09-01 Cancer
• Extension Study for Participants in Studies That Include Pembrolizumab Recruiting
  2022-501254-10-00 5 2018-08-24 Advanced tumors
• Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Recruiting
  2023-506987-15-00 9 2016-11-17 Metastatic Castration-Resistant Prostate Cancer
• Melatonin for prevention of agitation after surgery in children (MELA-PAED). Ended recruitment
  2024-517592-20-00 5 2026-05-30 Emergence delirium
• Safety and Efficacy of AT-004 in Patients with Acne Vulgaris Ended recruitment
  2025-521510-25-00 4 2026-01-13 Acne vulgaris
• A study of BMS-986504 in combination with Nab-p/Gem versus placebo in combination with Nab-p/Gem in untreated metastatic PDAC with homozygou … Ended recruitment
  2025-522598-12-00 10 2025-12-17 Untreated Metastatic Pancreatic Ductal Adenocarcinoma
• Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects with Alzheimer’s Disease (AD) Ended recruitment
  2024-519497-39-00 4 2025-10-03 Alzheimer's Disease
• Study of lunsekimig (SAR443765) compared with placebo in adults with high-risk asthma Ended recruitment
  2024-513959-33-00 4 2025-05-13 Asthma
• Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration- … Ended recruitment
  2024-513968-25-00 5 2025-04-28 Metastatic castration-resistant prostate cancer (mCRPC)
• A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-naïve Participants with Active Psoriatic Arthritis Ended recruitment
  2023-509239-19-00 5 2025-04-03 Active Psoriatic Arthritis
• Complete remission study Ended recruitment
  2024-519628-25-00 6 2025-04-03 Chronic rrhinosinusitis with nasal polyps
• Long-term, open-label study of SAR447537 (INBRX-101) in adults with alpha-1 antitrypsin deficiency emphysema Ended recruitment
  2023-508137-14-00 4 2025-03-11 Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
• Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation t … Ended recruitment
  2023-510458-18-00 6 2025-03-11 Asthma
• BONG: Reducing severe Breathlessness with Dronabinol in the severe and very severe chronic obstructive pulmonary disease patient group Ended recruitment
  2024-513593-22-00 10 2025-01-31 Chronic obstructive pulmonary disease
• A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of KBP-336 as an Adjunct to Diet and Exercise in Ob … Ended recruitment
  2024-517264-27-00 4 2024-12-13 Obesity
• An open-label study to assess reduction of daily asthma medication with tezepelumab in patients 12 to 80 years of age with severe asthma Ended recruitment
  2024-512113-41-00 5 2024-11-20 Severe Asthma
• A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheu … Ended recruitment
  2023-508077-85-00 5 2024-11-19 Polymyalgia Rheumatica
• Topical tacrolimus for the amelioration of breast cancer-related lymphedema: a randomized, double-blind, placebo-controlled phase II/III tri … Ended recruitment
  2023-503644-13-00 5 2024-09-09 Breast cancer-related lymphedema
• A Study on Diclofenac vs. Placebo for Knee Osteoarthritis Ended recruitment
  2024-510757-95-01 6 2024-08-01 Knee osteoarthritis
• A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended recruitment
  2023-503923-24-00 5 2024-07-22 Sjögren’s Syndrome With Moderate-toSevere Symptom State
• A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei … Ended recruitment
  2023-508306-15-00 5 2024-06-26 Alzheimer’s Disease

Showing 73–96 of 179 trials